Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study.
Fiche publication
Date publication
juillet 2023
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DROUILLARD Antoine
Tous les auteurs :
Frydman AE, Drouillard A, Soularue E, Dubreuil O, Zaanan A, Turpin A, Tougeron D, Doat S, Bachet JB
Lien Pubmed
Résumé
Approximately 10-20% of patients with gastroesophageal adenocarcinoma (GE-ADK) have HER2-positive tumors. The addition of trastuzumab to chemotherapy improves OS in patients with advanced disease. We investigated the effect of perioperative trastuzumab on survival outcomes.
Mots clés
Gastro-esophageal adenocarcinoma, HER2-positive, Perioperative chemotherapy, Trastuzumab
Référence
Dig Liver Dis. 2023 07 3;: